Company Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.

The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus.

It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.

Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences, Inc.

Country	United States
Founded	2015
IPO Date	Jun 21, 2018
Industry	Biotechnology
Sector	Healthcare
Employees	55
CEO	Christopher Kirk

Contact Details

Address: 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States
Phone	650 822 5600
Website	kezarlifesciences.com

Stock Details

Ticker Symbol	KZR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001645666
CUSIP Number	49372L100
ISIN Number	US49372L2097
Employer ID	47-3366145
SIC Code	2834

Key Executives

Name	Position
Dr. Christopher J. Kirk Ph.D.	Co-Founder, Chief Executive Officer and Director
Mark Schiller	Chief Operations Officer
Dr. Jack Taunton Ph.D.	Co-Founder

Latest SEC Filings

Date	Type	Title
Apr 3, 2026	SC14D9C	Filing
Apr 3, 2026	8-K	Current Report
Apr 1, 2026	SCHEDULE 13D/A	Filing
Mar 30, 2026	SC14D9C	Filing
Mar 30, 2026	8-K	Current Report
Mar 27, 2026	10-K	Annual Report
Mar 12, 2026	8-K	Current Report
Feb 13, 2026	SCHEDULE 13G/A	Filing
Feb 9, 2026	SCHEDULE 13G/A	Filing
Nov 14, 2025	SCHEDULE 13G/A	Filing

View All SEC Filings